ACP-204 for Hallucinations
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called ACP-204 to determine its effectiveness in reducing hallucinations in individuals with dementia related to Lewy bodies or Parkinson's disease. Participants will receive either a low dose, a higher dose of the treatment, or a placebo (a pill with no active medicine) to compare the effects. The study spans six weeks and aims to assess both the efficacy and safety of ACP-204. Suitable candidates have been diagnosed with dementia with Lewy bodies or Parkinson’s disease with dementia and experience hallucinations. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of participants.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that ACP-204 is likely to be safe for humans?
Research has shown that ACP-204, a treatment for hallucinations, appears safe. Early studies with healthy adults found it did not affect heart function, specifically the QT interval, which measures heart rhythm. This finding is a positive sign for heart safety. Further research in animals, such as monkeys and rats, showed that ACP-204 was well tolerated, even at high doses, with no harmful effects. Although human trials are ongoing, these findings suggest that ACP-204 could be a safe option for prospective trial participants.12345
Why do researchers think this study treatment might be promising?
Most treatments for hallucinations focus on managing symptoms through medications like antipsychotics, which often come with significant side effects. But ACP-204 works differently, targeting the underlying neurological pathways that contribute to hallucinations, potentially reducing these symptoms with fewer side effects. Researchers are excited about ACP-204 because its novel mechanism of action might offer quicker relief and improved tolerability compared to current treatments. By providing a new approach, ACP-204 could significantly enhance the quality of life for those experiencing hallucinations.
What evidence suggests that ACP-204 might be an effective treatment for hallucinations?
Studies have shown that ACP-204 can reduce hallucinations and delusions in people with Alzheimer's disease. This treatment has improved overall function and quality of life. Research indicates that ACP-204 is safe, as it does not significantly affect heart rhythms, which supports its use. Although information on ACP-204 for Lewy Body Dementia Psychosis (LBDP) is limited, the positive effects observed in Alzheimer's disease suggest it might also alleviate similar symptoms in LBDP. Early findings support its potential effectiveness, but further research is needed to confirm these benefits for LBDP.12346
Are You a Good Fit for This Trial?
This trial is for men and women aged 55 to 84 with Lewy Body Dementia Psychosis, who can consent or meet specific requirements. It's not for those with serious unstable conditions, in end-of-life care, suicidal tendencies, or psychosis due to other causes.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either ACP-204 (30 mg or 60 mg) or placebo once daily for 6 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ACP-204
Find a Clinic Near You
Who Is Running the Clinical Trial?
ACADIA Pharmaceuticals Inc.
Lead Sponsor